New drug for enterovirus passes first safety check in healthy volunteers
NCT ID NCT06444048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety of a new drug called EV68-228-N in 36 healthy adults aged 18 to 49. Participants received a single dose of the drug or a placebo by IV, and were monitored for side effects for up to 29 days. The goal was not to treat any disease, but to gather information on how safe the drug is and how it behaves in the body before moving to larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENTEROVIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201-1509, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-0011, United States